hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06283667 id: NN9536-4872 id: U1111-1266-3863 type: OTHER domain: World Health Organization (WHO) briefTitle: Special Use - Results Surveillance on Long-term Use With Wegovy® overallStatus: NOT_YET_RECRUITING date: 2024-02-22 date: 2025-06-30 date: 2028-01-31 date: 2024-02-28 date: 2024-02-28 name: Novo Nordisk A/S class: INDUSTRY briefSummary: The purpose of the study is to investigate the safety and effectiveness of Wegovy® in patients with obesity disease under real-world clinical practice in Japan. Participants will get Wegovy® as prescribed by the study doctor. The study will last for about 4 years. Participant will be in the study for about 2 years (104 weeks). conditions: Obesity studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1000 type: ESTIMATED name: Semaglutide measure: Number of Adverse Reactions (ARs) measure: Number of Adverse Events (AEs) measure: Number of serious adverse events (SAEs) measure: Number of Serious Adverse Reactions (SARs) measure: Change in body weight (Percent (%)) measure: Change in body weight (Kilograms (Kg)) measure: Change in waist circumference measure: Change in BMI (Body Mass Index) measure: Change in body weight after treatment discontinuation sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Novo Nordisk Investigational Site city: Tokyo state: Chiyoda City zip: 100-0005 country: Japan lat: 35.6895 lon: 139.69171 hasResults: False
nctId: NCT06283654 id: VUmc 2018.539 briefTitle: Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation acronym: relievED overallStatus: COMPLETED date: 2018-09-30 date: 2021-09-30 date: 2023-01-31 date: 2024-02-28 date: 2024-04-26 name: Amsterdam UMC, location VUmc class: OTHER briefSummary: In this study, the researchers explored a new approach to manage atrial fibrillation, a disease that affects millions worldwide. The goal was to see if using a simple handheld ECG device for monitoring heart rhythm could help patients avoid unnecessary visits to the emergency department (ED) after undergoing a common procedure known as pulmonary vein isolation (PVI). This procedure is often used to treat AF, but following it patients frequently visit the ED due to concerns about their heart rhythm, which can strain healthcare resources. The researchers proved a group of patients with a 1-lead ECG device , which allowed users to check their heart rhythm at any time. The researchers compared the ED utilization over a year with that of patients who received standard care after PVI. The hope was that by using the 1-lead ECG device, patients could better manage their condition from home and only seek medical help when truly necessary. conditions: Atrial Fibrillation studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 204 type: ACTUAL name: 1-lead ECG measure: number of ED visits measure: ratio of the number of cardioversions emergency vs planned sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Amsterdam UMC -vumc city: Amsterdam country: Netherlands lat: 52.37403 lon: 4.88969 hasResults: False
nctId: NCT06283641 id: NN8022-7780 id: U1111-1289-9747 type: OTHER domain: World Health Organization (WHO) briefTitle: Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan. overallStatus: ENROLLING_BY_INVITATION date: 2024-02-23 date: 2025-02-28 date: 2025-02-28 date: 2024-02-28 date: 2024-04-04 name: Novo Nordisk A/S class: INDUSTRY briefSummary: This is a non-interventional study to evaluate the safety and effectiveness of Saxenda® in obese adults and adolescents in Taiwan. The participants will recieve Saxenda® treatment which is a medicine that doctors can already prescribe.
The study will last for about 26 weeks. conditions: Obesity studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 288 type: ESTIMATED name: Liraglutide measure: Incidence of adverse events (AEs) by preferred term (PT) measure: Number of adverse drug reaction (ADRs) measure: Number of serious adverse events (SAEs) and serious adverse drug reactions (SADRs) measure: Number of unexpected AEs and unexpected ADRs measure: Number of unexpected SAEs and unexpected SADRs measure: Dose and exposure of liraglutide after initiation and reasons if not escalate to liraglutide 3.0 miligram (mg) for maintenance as specified in the product label measure: Body weight loss Percent (%) (Adult) measure: Body weight loss (%) (Adult) measure: Body weight loss Kilogram(Kg) (Adult) measure: Body weight loss (kg) (Adult) measure: The proportion of adult subjects losing at least 5% of baseline body weight measure: The proportion of adult subjects losing at least 5% of baseline body weight measure: The proportion of adult subjects losing more than 10% of baseline body weight measure: The proportion of adult subjects losing more than 10% of baseline body weight measure: The proportion of losing at least 5% of baseline body weight from adult subjects whose maintenance dose of 3 mg, 12- week Saxenda® measure: Change in body mass index (BMI) (kg/m^2) (Adolescent) measure: Change in body mass index (BMI) (kg/m^2) (Adolescent) measure: Change in body mass index (BMI) (%) (Adolescent) measure: Change in body mass index (BMI) (%) (Adolescent) measure: Change in body mass index standard deviation score (BMI SDS) (Adolescent) measure: Change in body mass index standard deviation score (BMI SDS) (Adolescent) measure: Body weight loss (%) (Adolescent) measure: Body weight loss (%) (Adolescent) measure: Body weight loss (kg) (Adolescent) measure: Body weight loss (kg) (Adolescent) measure: The proportion of adolescent subjects losing at least 4% of baseline BMI measure: The proportion of adolescent subjects losing at least 4% of baseline BMI measure: The proportion of adolescent subjects losing at least 10% of baseline BMI measure: The proportion of adolescent subjects losing at least 10% of baseline BMI measure: The proportion of losing at least 4% of baseline BMI from adolescent subjects whose maintenance dose of 3 mg or maximum tolerated dose, 12- week Saxenda® sex: ALL minimumAge: 12 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: National Taiwan University Hospital city: Taipei City zip: 100229 country: Taiwan lat: 25.04776 lon: 121.53185 facility: National Taiwan University Hospital city: Taipei City zip: 100 country: Taiwan lat: 25.04776 lon: 121.53185 hasResults: False
nctId: NCT06283628 id: STUDY00023737 briefTitle: Comparative Effectiveness of Two Different Approaches to Radiofrequency Ablation of Lumbar Medial Branch Nerves acronym: LMB-RFA overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-12 date: 2025-12 date: 2024-02-28 date: 2024-02-28 name: Milton S. Hershey Medical Center class: OTHER briefSummary: The purpose of this voluntary research study is to determine whether the parasagittal approach to lumbar medial branch (LMB) nerve radio frequency ablation (RFA) will have greater efficacy than the traditional approach to lumbar medial branch nerve radio frequency ablation. conditions: Lumbar Spondylosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The subjects with bilateral low back pain will undergo radiofrequency ablation of the lumbar medial branch nerves using one approach (traditional) on one side and different approach (parasagittal) on the other side. One arm will use the traditional approach on the left and the parasagittal approach on the right. The other arm will use parasagittal approach on the left and the traditional approach on the right, primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: We will do computer randomization for the sides for each approach for all the subjects. The subjects will be assigned numbers, and the particular procedural approach for each side will be concealed in the numbered envelopes. The numbers on the envelopes will correspond to the numbers assigned to the patients. The envelopes will be opened by a treating physician in the procedure room. The patient and the assessor (who will not be the treating physician) will not know which procedural approach was used for the sides. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 25 type: ESTIMATED name: Radiofrequency ablation of lumbar medial branch nerves. measure: The number of patients whose procedure was successful (gained 50% or more reduction in numeric rating pain (NRS) scores). measure: The number of patients whose procedure was successful (gained 50% or more reduction in numeric rating pain (NRS) scores). measure: The number of patients whose procedure was successful (gained 50% or more reduction in numeric rating pain (NRS) scores). measure: Oswestry Disability index (ODI) measure: Oswestry Disability index (ODI) measure: Oswestry Disability index (ODI) measure: Number of subjects who ceased requiring analgesia measure: Number of subjects who ceased requiring analgesia measure: Number of subjects who ceased requiring analgesia sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Penn State Hershey College of Medicine city: Hershey state: Pennsylvania zip: 17033 country: United States name: Nancy Ruth Jarbadan, BS role: CONTACT phone: 717-531-6135 email: njarbadan@pennstatehealth.psu.edu lat: 40.28592 lon: -76.65025 hasResults: False
nctId: NCT06283615 id: 2024-01-01 briefTitle: Effect of Vitamin D on Skeletal Muscle Function and Qol in Patients With Chronic Intestinal Failure/Insufficiency overallStatus: RECRUITING date: 2024-03-12 date: 2024-11-30 date: 2024-11-30 date: 2024-02-28 date: 2024-03-22 name: Jinling Hospital, China class: OTHER briefSummary: Eligible patients were randomized into two groups: Vitamin D group and Control group. Control group: routine treatment only, no additional vitamin D intervention therapy. Vitamin D group: In addition to the conventional treatment, additional intramuscular injection of vitamin D2 was given once every two weeks, each dose of 600,000 units, and the treatment lasted for 12 weeks.
The primary and secondary outcomes will be collected. conditions: Intestinal Failure studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 84 type: ESTIMATED name: Vitamin D measure: Quality of life score measure: Muscle function status measure: Serum vitamin D levels measure: Hepatic and renal function measure: Bone mineral density measure: Thyroid and parathyroid-related hormones measure: Nutritional status indicators measure: Number of participants with treatment-related adverse events sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Xinying Wang status: RECRUITING city: Nanning state: Jiangsu zip: 210002 country: China name: Xinying Wang, MD role: CONTACT phone: +86 13913028866 email: wangxinying@nju.edu.cn name: Xuejin Gao, MD role: CONTACT phone: +86 18251937684 email: 547625433@qq.com name: Xinying Wang, MD role: PRINCIPAL_INVESTIGATOR name: Xuejin Gao, MD role: SUB_INVESTIGATOR lat: 22.81667 lon: 108.31667 hasResults: False
nctId: NCT06283602 id: 2020/17 briefTitle: Oral Health in Children and Adolescents With Obesity and Normal Weight overallStatus: COMPLETED date: 2020-01-01 date: 2021-03-05 date: 2021-04-29 date: 2024-02-28 date: 2024-02-28 name: Kahramanmaras Sutcu Imam University class: OTHER briefSummary: We aimed to compare the oral health status (dmft/DMFT index, IDCAS-II, BEWE, plaque index, gingival index, probing depth) between normal-weight (NW) and obese (OW) children/adolescents.
82 participants aged 6-16 years were concluded in this cross-sectional study. The children/adolescents were classified according to the body mass index (BMI): NW (n=41) and OW (n=41). Caries experience was assessed by the International Caries Detection and Assessment System (ICDAS-II), decay, missing, filling teeth (dmft) for the primary teeth and (DMFT) for the permanent teeth, erosive tooth wear using Basic Erosive Wear Examination (BEWE), Plaque Index (PI) and Gingival Index (GI), Probing Depth (PD). conditions: Pediatric Obesity conditions: Pediatric Dentistry studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 82 type: ACTUAL name: oral health status measure: the results of DMFT, plaque and gingival indies measure: the results of dmft, BEWE, ICDAS-II, probing dept measure: Comparison of demographic attributes between obese and normal weights measure: biochemical parameters of obese individuals measure: other biochemical parameters of obese individuals sex: ALL minimumAge: 6 Years maximumAge: 16 Years stdAges: CHILD facility: Aslı Soğukpınar Önsüren city: Mersin country: Turkey lat: 36.79526 lon: 34.61792 hasResults: False
nctId: NCT06283589 id: INZ701-401 briefTitle: The SEAPORT 1 Study: Evaluation of the Safety and Tolerability of INZ-701 in Adults With End-Stage Kidney Disease Undergoing Hemodialysis overallStatus: RECRUITING date: 2024-02-12 date: 2024-07-19 date: 2024-08-19 date: 2024-02-28 date: 2024-02-28 name: Inozyme Pharma class: INDUSTRY briefSummary: The purpose of this study is to determine if multiple doses of INZ-701, given once per week over 4 weeks are safe and increase pyrophosphate (PPi) levels in hemodialysis-dependent (HD) end stage kidney disease (ESKD) study participants who have low PPi levels. In addition, the effect of hemodialysis on the PK of INZ-701 and PPi levels will be evaluated. conditions: Calciphylaxis studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: The SEAPORT 1 (INZ701-401) study is a Phase 1, open-label study to evaluate the safety, pharmacokinetics, and pharmacodynamics of multiple doses of INZ-701, given once per week over 4 weeks, in study participants with end-stage kidney disease undergoing hemodialysis. primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: INZ-701 measure: Determine if INZ-701 increases PPi levels measure: Assess the Time to Maximum Serum Concentration (Tmax) measure: Assess the Maximum Serum Concentration (Cmax) of INZ-701 measure: Assess the Area under the concentration-time curve over the dosing interval (AUCtau) measure: Assess the Clearance after extravascular administration of drug (CL/F) sex: ALL minimumAge: 18 Years maximumAge: 69 Years stdAges: ADULT stdAges: OLDER_ADULT facility: South Florida Nephrology Research status: RECRUITING city: Coral Springs state: Florida zip: 33071 country: United States name: Ashgar Chaudhry, MD role: CONTACT phone: 954-510-7620 email: info@flkidney.com lat: 26.27119 lon: -80.2706 facility: Elixia Health status: RECRUITING city: Hollywood state: Florida zip: 33024 country: United States name: Steven Zeig role: CONTACT phone: 954-900-1101 email: info@elixiacrc.com lat: 26.0112 lon: -80.14949 hasResults: False
nctId: NCT06283576 id: PANCAID-00-08 briefTitle: Pancreatic Cancer Initial Detection Via Liquid Biopsy acronym: PANCAID overallStatus: ENROLLING_BY_INVITATION date: 2024-05-01 date: 2027-12-31 date: 2027-12-31 date: 2024-02-28 date: 2024-04-24 name: Karolinska University Hospital class: OTHER name: Umeå University briefSummary: The overall rationale of PANCAID is to provide a diagnostic blood test for early diagnosis of pancreatic cancer. With a set of different liquid biopsy methods, it is the aim to measure these markers in well-defined patient cohorts. For the entire series of these studies, the following groups are planned: 1) Histologically proven early-stage pancreatic cancer (e.g. T1a/b and T2 carcinomas \[N0M0\]); 2) Intraductal papillary mucinous neoplasia (IPMN) that were operated with verification of the benign, premalignant or malignant histology; 3) ordinary branched-duct IPMN; 4) individuals at risk (IAR) with and without IPMN, with and without known hereditary cancer gene (e.g. BRCA2); 5) a high risk group of patients with chronic pancreatitis, aged 55-65, who are heavy smokers (≥40 PY), with newly onset diabetes mellitus (NODM). conditions: Pancreatic Cancer conditions: IPMN, Pancreatic conditions: Individuals at Risk conditions: Chronic Pancreatitis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED name: Liquid biopsy measure: Cancer detection measure: Overall survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Gastrocentrum, KarolinskaUniversity Hospital city: Stockholm zip: 14186 country: Sweden lat: 59.33258 lon: 18.0649 hasResults: False
nctId: NCT06283563 id: 2023/5474 briefTitle: Online Physical Activity Tracking in Patients With Multiple Sclerosis overallStatus: NOT_YET_RECRUITING date: 2024-02-28 date: 2025-02-15 date: 2025-02-28 date: 2024-02-28 date: 2024-02-28 name: Inonu University class: OTHER briefSummary: This study aims to investigate the effects of regular remote monitoring of physical activity levels of individuals with multiple sclerosis on physical activity levels, psychological health, fatigue and quality of life. conditions: Multiple Sclerosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: Physical activity tracking name: No physical activity tracking measure: Smartphone pedometer measure: Smartphone pedometer measure: International Physical Activity Questionnaire - Short Form measure: International Physical Activity Questionnaire - Short Form measure: Beck Depression Inventory II measure: Beck Depression Inventory II measure: Beck Anxiety Inventory measure: Beck Anxiety Inventory measure: Fatigue Severity Scale measure: Fatigue Severity Scale measure: Multiple Sclerosis Quality of Life-54 measure: Multiple Sclerosis Quality of Life-54 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06283550 id: INNO-6052 briefTitle: Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-05 date: 2025-08 date: 2024-02-28 date: 2024-02-29 name: Innovaderm Research Inc. class: OTHER briefSummary: This study aims to evaluate the safety, efficacy and tolerability of abrocitinib in subjects with moderate to severe chronic hand eczema, and its effects on skin biomarkers using a noninvasive method of tape stripping. conditions: Chronic Hand Eczema studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 84 type: ESTIMATED name: Abrocitinib 200 mg name: Abrocitinib 100 mg name: Placebo measure: Change from baseline in hand modified Total Lesion Symptom Score (mTLSS) measure: Change from baseline in hand modified Total Lesion Symptom Score (mTLSS) measure: Reduction from baseline in hand Physician's Global Assessment (PGA) measure: Change from baseline in Hand Eczema Severity Index (HECSI) measure: Change from baseline in Extent of Disease affected with moderate to severe chronic hand eczema (CHE) measure: Patient Global Assessment (PaGA) measurements measure: Change from baseline in hand Dermatology Life Quality Index (DLQI) measure: Change from baseline in Quality of Life in Hand Eczema Questionnaire (QOLHEQ) measure: Change from baseline in pain Numerical Rating Scale (NRS) measure: Change from baseline in itch Numerical Rating Scale (NRS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Innovaderm Research Inc. city: Montréal state: Quebec zip: H2X 2V1 country: Canada name: Rosanna Ottoni, BSc role: CONTACT phone: 514-521-4285 phoneExt: 107 email: rottoni@innovaderm.com lat: 45.50884 lon: -73.58781 hasResults: False
nctId: NCT06283537 id: KÜBAP-01/2023-39 briefTitle: Online Episiotomy Simulation Training for Midwifery Students overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-03-01 date: 2024-05-30 date: 2024-02-28 date: 2024-02-28 name: Kastamonu University class: OTHER briefSummary: Purpose: To determine the effect of online episiotomy simulation training to midwifery students on their episiotomy application skills, satisfaction with the teaching method and self-confidence.
Method: This study is a randomized controlled experimental study. It will be conducted with third-year students studying at Kastamonu University Midwifery Department in the 2023-2024 period. In the research, all third-year students in the midwifery department (n=60) will be divided into 30 students into the online education group and 30 students into the face-to-face education group using a random sampling model. "Student Information Form", "Episiotomy Skill Evaluation Form" and "Student Satisfaction and Self-Confidence in Learning Scale" will be used to collect data. conditions: Training Group, Sensitivity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A comparative randomized controlled trial primaryPurpose: OTHER masking: SINGLE maskingDescription: After all students in the face-to-face education and online education groups complete their applications, the students will practice on the material one by one in the school environment and will be evaluated through the Episiotomy Skill Evaluation Form. In the evaluation, a blinding technique will be used to prevent the person conducting the study interventions from making an evaluation in favor of the intervention group. For this purpose, the faculty member conducting the research initiatives will not take part in the evaluation, instead the evaluation will be made by two different field experts. The experts to be consulted for the evaluation will consist of people working as academicians in the field of obstetrics, nursing and midwifery. After the evaluation, students will have to fill out the survey (Student Information Form) and scale (Student Satisfaction and Self-Confidence in Learning Scale). whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: Effect of training method measure: episiotomy skill performances measure: Satisfaction with education measure: Self-confidence in learning sex: FEMALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False